Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07112872 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT07112872: Recruiting Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Hoffmann-La Roche.
NCT07112872 is a Phase 2 study of Type 2 Diabetes Mellitus that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 240 participants, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07112872, a Phase 2 study of Type 2 Diabetes Mellitus, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG RO7795081
Study Locations (20)
California
- Orange County Research Center - Lake Forest
- Prospective Research Innovations Inc. - Rancho Cucamonga
- Encompass Clinical Research - Spring Valley
Florida
- K2 Medical Research South Orlando, LLC - Clermont
- Center for Diabetes, Obesity and Metabolism Inc - Pembroke Pines
North Carolina
- Accellacare of Piedmont Healthcare - Statesville
- Accellacare of Wilmington, LLC - Wilmington
Tennessee
- Alliance for Multispecialty Research. LLC - Knoxville
- Clinical Research Associates - Nashville
Texas
- Texas Diabetes & Endocrinology, P.A. - Austin
- Apex Mobile Clinical Research - Bellaire
Arizona
- Arizona Liver Health - Tucson - Tucson
Connecticut
- Chase Medical Research - Waterbury
District of Columbia
- Emerson Clinical Research Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2027-02-08 |
| Phase | Phase 2 |
What NCT07112872 shows while recruiting
NCT07112872 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07112872 names 20 study sites across 14 states, led by California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07112872 about?
NCT07112872 is a clinical study titled "A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes". This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
What is the current status of trial NCT07112872?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-08-19. Estimated completion is 2027-02-08.
What conditions does trial NCT07112872 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT07112872?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), RO7795081 (DRUG).
Who is sponsoring clinical trial NCT07112872?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07112872 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07112872's enrollment target sits among peer trials
240 33rd of 130 higher than 98 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
-
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI